Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Karin Hartog"'
Autor:
Aemro Kassa, Antu K Dey, Pampi Sarkar, Celia Labranche, Eden P Go, Daniel F Clark, Yide Sun, Avishek Nandi, Karin Hartog, Heather Desaire, David Montefiori, Andrea Carfi, Indresh K Srivastava, Susan W Barnett
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e76139 (2013)
Entry of HIV-1 into target cells requires binding of the viral envelope glycoprotein (Env) to cellular receptors and subsequent conformational changes that culminates in fusion of viral and target cell membranes. Recent structural information has rev
Externí odkaz:
https://doaj.org/article/b7c0af66bfd14154b3573bb1a9e8c474
Autor:
Antu K Dey, Brian Burke, Yide Sun, Klara Sirokman, Avishek Nandi, Karin Hartog, Ying Lian, Anthony R Geonnotti, David Montefiori, Michael Franti, Grégoire Martin, Andrea Carfi, Pascal Kessler, Loïc Martin, Indresh K Srivastava, Susan W Barnett
Publikováno v:
PLoS ONE, Vol 7, Iss 1, p e30233 (2012)
The identification of HIV-1 envelope glycoprotein (Env) structures that can generate broadly neutralizing antibodies (BNAbs) is pivotal to the development of a successful vaccine against HIV-1 aimed at eliciting effective humoral immune responses. To
Externí odkaz:
https://doaj.org/article/8de4cde9f4c94164b95e696ae0582869
Autor:
Andria G. M. Langenberg, Steve Kohl, Rose E. Sekulovich, Cheryl Goldbeck, Karin Hartog, Edwin D. Charlebois, Rae Lyn Burke, Mavash Sigouroudinia
Publikováno v:
The Journal of Infectious Diseases. 181:335-339
The humoral response to a herpes simplex virus (HSV) type 2 subunit vaccine containing recombinant glycoproteins B (gB 2 ) and D (gD 2 ) was tested in 3 groups of patients. These included HSV-seronegative, HSV-1-seropositive, and HSV-2-seropositive i
Autor:
Celia C. LaBranche, Aemro Kassa, Avishek Nandi, Indresh K. Srivastava, Eden P. Go, Yide Sun, Pampi Sarkar, Heather Desaire, Daniel F. Clark, Antu K. Dey, Susan W. Barnett, Karin Hartog, Andrea Carfi, David C. Montefiori
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e76139 (2013)
PLoS ONE
PLoS ONE
Entry of HIV-1 into target cells requires binding of the viral envelope glycoprotein (Env) to cellular receptors and subsequent conformational changes that culminates in fusion of viral and target cell membranes. Recent structural information has rev
Autor:
Andrea Carfi, Indresh K. Srivastava, A Kassa, Antu K. Dey, Celia C. LaBranche, Karin Hartog, Susan W. Barnett, Avishek Nandi, David C. Montefiori, Yide Sun
Publikováno v:
Retrovirology
Retrovirology, Vol 9, Iss Suppl 2, p P18 (2012)
Retrovirology, Vol 9, Iss Suppl 2, p P18 (2012)
Methods Here, we designed disulfide-stabilized recombinant HIV1 subtype B (SF162) envelope glycoproteins (Env), gp120 and gp140, by insertion of site-specific cysteine pairs between two layers (layer 1 and 2) in inner domain of gp120. In addition, we
Autor:
Loïc Martin, Indresh K. Srivastava, Antu K. Dey, Karin Hartog, Brian Burke, Michael Franti, Avishek Nandi, Andrea Carfi, Anthony R. Geonnotti, Ying Lian, Pascal Kessler, Yide Sun, Susan W. Barnett, Klara Sirokman, Grégoire Martin, David C. Montefiori
Publikováno v:
PLoS ONE
PLoS ONE, Public Library of Science, 2012, 7 (1), pp.e30233. ⟨10.1371/journal.pone.0030233⟩
PLoS ONE, Vol 7, Iss 1, p e30233 (2012)
PLoS ONE, 2012, 7 (1), pp.e30233. ⟨10.1371/journal.pone.0030233⟩
PLoS ONE, Public Library of Science, 2012, 7 (1), pp.e30233. ⟨10.1371/journal.pone.0030233⟩
PLoS ONE, Vol 7, Iss 1, p e30233 (2012)
PLoS ONE, 2012, 7 (1), pp.e30233. ⟨10.1371/journal.pone.0030233⟩
The identification of HIV-1 envelope glycoprotein (Env) structures that can generate broadly neutralizing antibodies (BNAbs) is pivotal to the development of a successful vaccine against HIV-1 aimed at eliciting effective humoral immune responses. To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a01d1596d51a05cabae26f183322d186
https://hal-cea.archives-ouvertes.fr/cea-02530537
https://hal-cea.archives-ouvertes.fr/cea-02530537
Autor:
Yide Sun, Susan W. Barnett, Brian Burke, Antu K. Dey, Indresh K. Srivastava, David C. Montefiori, Karin Hartog, Jonathan L. Heeney
Publikováno v:
Vaccine. 30(17)
Identification of optimal antigen(s) and adjuvant combination(s) to elicit potent, protective, and long-lasting immunity has been a major challenge for the development of effective vaccines against chronic viral pathogens, such as HIV-1, for which th
Autor:
Yide Sun, Elaine Kan, Brian Burke, Leonidas Stamatatos, Indresh K. Srivastava, Jimna Cisto, Susan Hilt, Susan W. Barnett, Ying Lian, R. Holland Cheng, Karin Hartog, Jeffrey B. Ulmer, Zohar Biron, Victoria Sharma
Publikováno v:
Virology. 372(2)
We previously reported that an envelope (Env) glycoprotein immunogen (o-gp140DeltaV2SF162) containing a partial deletion in the second variable loop (V2) derived from the R5-tropic HIV-1 isolate SF162 partially protected vaccinated rhesus macaques ag
Autor:
Xavier Paliard, Barbara Doe, Alexander Y. Lee, Christopher M. Walker, Mark Selby, Rae Lyn Burke, Karin Hartog
Publikováno v:
Virology. 282(1)
Loading of most endogenous peptides on major histocompatibility complex class I molecules is conditional on their transport into the endoplasmic reticulum (ER) by the peptide transporter TAP. We describe an HSV-2/1 cross-reactive cytotoxic T-cell (CT
Autor:
Jeffrey B. Ulmer, R. Holland Cheng, Zohar Biron, Yide Sun, Brian Burke, Indresh K. Srivastava, Victoria Sharma, Karin Hartog, Ruben Diaz-Avalos, Ying Lian, Jimna Cisto, Elaine Kan, Susan W. Barnett, Leonidas Stamatatos, Susan Hilt
Publikováno v:
Virology. 381:287
Corrigendum to “Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates” [Virology 372 (2008) 273–290] Indresh K. Srivastava ⁎, Elaine Kan , Yide Sun , Victoria A. Sharma , Jimna Cisto , Brian